Loading articles...
Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
Elecoglipron, an investigational oral GLP-1 receptor agonist, demonstrated reductions in HbA1c and body weight in phase 2 trials.
GLP-1 Receptor Agonist Use Varies Widely for Youth Type 2 Diabetes
Geographic variation in GLP-1 receptor agonist prescribing for youths with type 2 diabetes across the US highlights disparities in care.
Combination GLP-1RA and SGLT2i May Offer Additive Benefits in T2DM
Combination therapy with GLP-1RAs and SGLT2i may provide additive benefits in type 2 diabetes, particularly for cardiovascular and renal outcomes.
Omnipod 5 Improves CGM Metrics, Reduces Hypoglycaemia in Diabetes
A real-world study of the Omnipod 5 automated insulin delivery system showed improvements in time in range and reduced hypoglycaemia.
Activism Essential for Scientific Freedom in ADA Controversy
A recent commentary argues that activism is necessary to protect scientific freedom amidst controversies involving the American Diabetes Association.
Conflicts of Interest Detrimental in GLP-1 Therapy Guidance
A new analysis reveals conflicts of interest among authors of GLP-1 therapy guidance documents, potentially affecting recommendations.
Diabetes Increases Post-Transplant Mortality Risk
Diabetes, including post-transplant diabetes mellitus (PTDM), is linked to increased cardiovascular events, graft dysfunction, and mortality after organ transplantation.
Orforglipron Oral GLP-1 Shows Efficacy in Phase 3 T2D Trials
Oral GLP-1 receptor agonist orforglipron demonstrated significant reductions in HbA1c and body weight in Phase 3 trials for type 2 diabetes.
Ozempic Mouth: Understanding Xerostomia and Oral Health Risks
Semaglutide's impact on salivary flow can lead to xerostomia, increasing risks of dental caries and periodontal disease. Management focuses on symptomatic relief and preventive oral care.